Similar Posts
July 2015: Innokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG
ByInnokeys
Innokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG • The acquisition enables Innokeys to fully lead clinical and commercial development…
Daiichi Sankyo Enrolls First Patient in Nimotuzumab Phase 3 Clinical Trials
ByInnokeys
Tokyo, Japan (April 25, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has been enrolled in…
Webinar – Nimotuzumab for Head and Neck Cancer Indication: A randomized phase 3 trial of Nimotuzumab in locally advanced head and neck cancer
ByInnokeys
Speaker: Prof. Dr. Kumar Prabhash, Medical Oncologist in Tata Memorial Hospital India The webinar was attended by more than 50…
New Marketing Authorization Approval in Cambodia for new indication of locally advanced unresectable or metastatic pancreatic cancer.
ByInnokeys
On 24 Sep 2019, Cambodia Ministry of Health approved new marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer for…
Webinar – Current Treatment of Locally Advanced Head and Neck Cancer and The Result of Randomized Phase III Study of Nimotuzumab in Locally Advanced Head and Neck Cancer
ByInnokeys
Speakers: 1. Prof. Iyer Narayanan Gopalakrishna, Head and neck surgeon in National Cancer Centre and Singapore General Hospital 2. Prof. Dr. Kumar…
Webinar – Clinical Experience of Using Nimotuzumab in Nasopharyngeal Cancer
ByInnokeys
Speaker: Dr. dr. Andhika Rachman, Sp.Pd-KHOM from MRCCC Siloam Hospital Indonesia